New gene therapy addresses primary cellular deficit associated with limb-girdle muscular dystrophy 2B

By | January 5, 2022
Children’s National Hospital experts developed a new pre-clinical gene therapy for a rare disorder, known as limb-girdle muscular dystrophy (LGMD) 2B, that addresses the primary cellular deficit associated with this disease.